ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstracts tagged "Effective"

  • Abstract Number: 500 • 2015 ACR/ARHP Annual Meeting

    Ofatumumab for Rheumatoid Arthritis: A Cochrane Systematic Review and Meta-Analysis

    Vidhu Anand1, Sachit Anand2, Sushil Garg3, Maria A. Lopez-Olivo4 and Jasvinder A. Singh5, 1University of Minnesota, Minneapolis, MN, 2All India Institute of Medical Sciences, New Delhi, India, 3The University of Minnesota, Minneapolis, MN, 4General Internal Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX, 5University of Alabama at Birmingham, Birmingham, AL

    Background/Purpose: Ofatumumab is a unique anti-CD20 monoclonal antibody with its epitope more proximal and distinct from the epitope recognized by rituximab or by other anti-CD20…
  • Abstract Number: 481 • 2014 ACR/ARHP Annual Meeting

    Efficacy and Safety of Etanercept in Rheumatoid Arthritis Patients over 75 Years Old

    Satoru Kodama, Satoshi Ito, Akira Murasawa, Kiyoshi Nakazono and Daisuke Kobayashi, Niigata Rheumatic Center, Shibata, Japan

    Background/Purpose Early introductions of biologics in early rheumatoid arthritis (RA) patients are well documented, but there are few reports of biologics use in established elderly…
  • Abstract Number: 2611 • 2014 ACR/ARHP Annual Meeting

    Short Term Efficacy of Tumor Necrosis Factor Inhibitors in Patients with non–radiographic Axial Spondylarthritis and  ankylosing  Spondylitis; Results from Turkbio Registry

    Pinar Cetin1, Umut Kalyoncu2, Bunyamin Kisacik3, Ismail Sari1, Dilek Solmaz4, Omer Karadag2, Ahmet Mesut Onat3, Gezmis Kimyon5, Levent Kilic6, Fatos Onen1, Sedat Kiraz2, Merih Birlik1, Ihsan Ertenli2, Omer Nuri Pamuk7 and Nurullah Akkoc1, 1Rheumatology, Dokuz Eylul University School of Medicine, Izmir, Turkey, 2Rheumatology, Hacettepe University School of Medicine, Ankara, Turkey, 3Rheumatology, Gaziantep University School of Medicine, Gaziantep, Turkey, 4Department of Internal Medicine, Division of Rheumatology, Namik Kemal University School of Medicine, Tekirdag, Turkey, 5Department of Rheumatology, Gaziantep University School of Medicine, Gaziantep, Turkey, 6Rheumatology, HacettepeUniversity School of Medicine, Ankara, Turkey, 7Department of Rheumatology, Trakya University School of Medicine, Edirne, Turkey

    Background/Purpose Axial spondylarthritis (AxSpA) has been proposed as an umbrella term for ankylosing spondylitis (AS) and non-radiographic (nr) AxSpA). This new concept makes diagnosis of…
  • Abstract Number: 2478 • 2014 ACR/ARHP Annual Meeting

    Analysis of the Clinical Sustained Response after Retreatment with a Lower Dose of Rituximab in Patients with Chronic Inflammatory Arthropathies

    M. Victoria Hernández1, Andrea Cuervo1, Sonia Cabrera1, Jose Inciarte-Mundo1, Julio Ramirez1, Virginia Ruiz-Esquide1, Juan D. Cañete2 and Raimon Sanmarti1, 1Arthritis Unit. Rheumatology Department, Hospital Clínic of Barcelona, Barcelona, Spain, 2Rheumatology, Hospital Clinic, Barcelona, Spain

    Background/Purpose: The dosage of rituximab (RTX) approved for the treatment of active rheumatoid arthritis (RA) is two intravenous (iv.) 1 g infusions, separated by two…
  • Abstract Number: 1868 • 2014 ACR/ARHP Annual Meeting

    Can DAS 28 at 3 Months after the 1st Biologic Therapy Predict Subsequent Sustainable Clinical Remission in Polyarticular Juvenile Idiopathic Arthritis Patients?

    Tomohiro Kubota1, Syuji Takei2, Tsuyoshi Yamatou3, Tomokazu Nagakura4, Hiroyuki Imanaka3, Yukiko Nonaka3, Tomoko Takezaki3, Harumi Akaike3 and Mio Matsuura5, 18-35-1 Sakuragaoka, Kagoshima University Hospital, Kagoshima City, Japan, 2School of Health Sciences, Faculty of Medicine, Kagoshima University, Kagoshima, Japan, 3Department of Pediatrics, Kagoshima University Hospital, Kagoshima, Japan, 4Department of Pediatrics, House of Meguminoseibo, Usuki, Japan, 5Kagoshima University, Kagoshima-Shi, Japan

    Background/Purpose:             To avoid the progression of joint damage, early decision making is important in JIA patients who failed to achieve sustainable clinical remission by…
  • Abstract Number: 1532 • 2014 ACR/ARHP Annual Meeting

    Efficacy of the Subcutaneous Formulation of Abatacept/Orencia in Rheumatoid Arthritis, a Single-Center Italian Experience

    Rossella Reggia1, Franco Franceschini1, Angela Tincani2 and Ilaria Cavazzana1, 1AO Spedali Civili, Rheumatology and Clinical Immunology Unit, Brescia, Italy, 2Rheumatology and Clinical Immunology, Spedali Civili and University of Brescia, Brescia, Italy

    Background/Purpose Abatacept is a selective T cell costimulation modulator indicated for moderately to severely active Rheumatoid Arthritis (RA). Since August 2013 is available in Italy…
  • Abstract Number: 2628 • 2013 ACR/ARHP Annual Meeting

    Immunogenicity Of Infliximab Modulates Efficacy and Safety In Behcet’s Disease Patients With Uveitis

    Mitsuhiro Takeno1, Kayo Terauchi1, Yohei Kirino1,2, Ryusuke Yoshimi1, Nobuhisa Mizuki2, Etsuko Shibuya3 and Yoshiaki Ishigatsubo2, 1Department of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine, Yokohama, Japan, 2Yokohama City University Graduate School of Medicine, Yokohama, Japan, 3Department of Ophthalmology and Visual Science, Yokohama City University Graduate School of Medicine, Yokohama, Japan

    Background/Purpose: Infliximab (IFX) suppresses ocular attacks in Behcet’s disease (BD) with uveitis, resulting in favorable long-term visual prognosis. However, some patients had ocular attacks which…
  • Abstract Number: 2384 • 2013 ACR/ARHP Annual Meeting

    Variability In Patient Characteristics and Outcomes In Rheumatoid Arthritis Upon Infliximab Treatment Based On The Size Of Biologic Treatment Registry Site

    J. Carter Thorne1, William G. Bensen2, Sanjay Dixit3, Rafat Y. Faraawi3,4, Dalton E. Sholter5, Maqbool K. Sheriff6, Philip Baer7, Denis Choquette8, Boulos Haraoui8,9, Algis Jovaisas10, Emmanouil Rampakakis11,12, John S. Sampalis11,12, May Shawi13, Francois Nantel14, Allen J. Lehman15 and Susan M. Otawa15, 1Southlake Regional Health Centre, Newmarket, ON, Canada, 2Department of Medicine, Division of Rheumatology, Clinical Professor, McMaster University, Hamilton, ON, Canada, 3McMaster University, Hamilton, ON, Canada, 4Rheumatologist, KW Musculoskeletal Research Inc., Kitchener, ON, Canada, 5Rheumatology Associates, Edmonton, AB, Canada, 6Nanaimo Regional General Hospital, Nanaimo, BC, Canada, 7Private Practice, Scarborough, ON, Canada, 8Rheumatology, Institut de rhumatologie de Montréal (IRM), Montréal, QC, Canada, 9Department of Medicine, Centre Hospitalier de l’Université de Montréal, Montréal, QC, Canada, 10Division of Rheumatology, University of Ottawa, Ottawa, ON, Canada, 11JSS Medical Research, Montreal, QC, Canada, 12Jewish General Hospital, McGill University, Montreal, QC, Canada, 13Medical Affairs, Janssen Canada Inc, Toronto, ON, Canada, 14Janssen Inc., Toronto, ON, Canada, 15Medical Affairs, Janssen Inc., Toronto, ON, Canada

    Background/Purpose: Efficacy of TNFi agents in the management of rheumatoid arthritis (RA) has been demonstrated in numerous controlled clinical trials. Variations with respect to patient…
  • Abstract Number: 1550 • 2013 ACR/ARHP Annual Meeting

    Validation Of The Ankylosing Spondylitis Disease Activity Score and Effectiveness Of Infliximab In The Treatment Of Ankylosing Spondylitis Over 4 Years: The Canadian Experience

    Proton Rahman1, Denis Choquette2, Majed M. Khraishi3, William G. Bensen4, Saeed A. Shaikh5, Dalton E. Sholter6, Maqbool K. Sheriff7, Emmanouil Rampakakis8, John S. Sampalis8, Francois Nantel9, Susan M. Otawa10, Allen J. Lehman10 and May Shawi11, 1Faculty of Medicine, Memorial University of Newfoundland, St. John's, NF, Canada, 2Rheumatology, Institut de rhumatologie de Montréal (IRM), Montréal, QC, Canada, 3Nexus Clinical Research, St John's, NF, Canada, 4Department of Medicine, Division of Rheumatology, Clinical Professor, McMaster University, Hamilton, ON, Canada, 5Medicine, McMaster University, St Catharines, ON, Canada, 6Rheumatology Associates, Edmonton, AB, Canada, 7Nanaimo Regional General Hospital, Nanaimo, BC, Canada, 8JSS Medical Research, Montreal, QC, Canada, 9Janssen Inc., Toronto, ON, Canada, 10Medical Affairs, Janssen Inc., Toronto, ON, Canada, 11Medical Affairs, Janssen Canada Inc, Toronto, ON, Canada

    Background/Purpose: The efficacy of anti-TNF in the management of Ankylosing Spondylitis (AS) has been demonstrated in numerous controlled clinical trials. The objective of this study…
  • Abstract Number: 1528 • 2013 ACR/ARHP Annual Meeting

    Patient-Tailored Dose Reduction Of Tumor Necrosis Factor-Alpha Blocking Agents In Ankylosing Spondylitis Patients With Stable Low Disease Activity

    Suzanne Arends1,2, Eveline van der Veer3, Fleur B.S. Kamps4, Monique Efde2, Martha K. Leijsma4, Hendrika Bootsma1, Elisabeth Brouwer5 and Anneke Spoorenberg2,4, 1Rheumatology and Clinical Immunology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands, 2Rheumatology, Medical Center Leeuwarden, Leeuwarden, Netherlands, 3Laboratory Medicine, University Medical Center Groningen, Groningen, Netherlands, 4Rheumatology and Clinical Immunology, University Medical Center Groningen, Groningen, Netherlands, 5Dept. of Rheumatology and Clinical Immunology, University Medical Center Groningen, Groningen, Netherlands

    Background/Purpose:  Tumor necrosis factor-alpha (TNF-α) blocking agents are very effective in controlling inflammation and improving clinical assessments in patients with ankylosing spondylitis (AS). In view…
  • Abstract Number: 1516 • 2013 ACR/ARHP Annual Meeting

    Safety and Efficacy Of Etanercept In Early Non-Radiographic Axial Spondyloarthritis: A Randomized, Double-Blind, Placebo-Controlled Trial At 24 Weeks

    Maxime Dougados1, Désirée van der Heijde2, Joachim Sieper3, Jürgen Braun4, Walter P. Maksymowych5, Gustavo Citera6, James Cheng-Chung Wei7, Jan Lenaerts8, Ronald Pedersen9, Randi Bonin10, Ehab Y. Mahgoub10, Bonnie Vlahos10 and Jack Bukowski11, 1Rheumatology B Department, Paris-Descartes University, Cochin Hospital, Paris, France, 2Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 3Charité Universitätsmedizin Berlin, Berlin, Germany, 4Rheumazentrum Ruhrgebiet, Herne, Germany, 5Medicine, University of Alberta, Edmonton, AB, Canada, 6Rheumatology, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, 7Institute of Medicine, Chung Shan Medical University Hospital, Taichung, Taiwan, 8Reuma Instituut, Hasselt, Belgium, 9Specialty Care, Pfizer Inc, Collegeville, PA, 10Pfizer Inc, Collegeville, PA, 11Department of Specialty Care, Pfizer Inc, Collegeville, PA

    Background/Purpose: Limited data are available on the efficacy of anti-TNF agents in non-radiographic axial spondyloarthritis (nr-axSpA). The objective of this analysis is to compare the…
  • Abstract Number: 1476 • 2013 ACR/ARHP Annual Meeting

    Effectiveness Of Etanercept In Elderly Patients With Rheumatoid Arthritis: A Single Center Retrospective Study

    Arthur N. Lau1, Alpesh Shah2, Melissa Deamude3, Cynthia Mech4, Robert Bensen5 and William G. Bensen6, 1Rheumatology and Clinical Epidemiology, Division of Rheumatology, McMaster University, Hamilton, ON, Canada, 2Epidemiology and Biostatistics, University of Western Ontario, MSc in Clinical Epidemiology, University of Western Ontario, London, ON, Canada, 3Dr. William G. Bensen, Rheumatology Health Team, St. Joseph's Hospital Hamilton, Hamilton, ON, Canada, 4Dr. William G. Bensen, Rheumatology Health Team, Dr. Bensen's Rheumatology Clinic, Hamilton, ON, Canada, 5Rheumatology Health Team, Dr. Bensen's Rheumatology Clinic, Hamilton, ON, Canada, 6Department of Medicine, Division of Rheumatology, Clinical Professor, McMaster University, Hamilton, ON, Canada

    Background/Purpose: Biological drugs have dramatically improved the prognosis of rheumatoid arthritis (RA), especially in those with early disease. These patientsare often in younger age with fewer…
  • Abstract Number: 1339 • 2013 ACR/ARHP Annual Meeting

    Efficacy and Safety Of Biologics Agents For Patients With Rheumatoid Arthritis and Hepatitis B Carrier

    Masahiro Tada1, Tatsuya Koike2, Akihiro Tamori3, Tadashi Okano1, Yuko Sugioka1, Kenji Mamoto1, Kentaro Inui4 and Hiroaki Nakamura1, 1Orthopedic Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan, 2Rheumatosurgery, Osaka City University Graduate School of Medicine, Osaka, Japan, 3Hepatiology, Osaka City University Graduate School of Medicine, Osaka, Japan, 4Orhtopedic Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan

    Background/Purpose: Biologics suppress hepatitis B virus (HBV) replication and play an important role in eradicating HBV by stimulating HBV-specific cytotoxic T-cell responses. We found that…
  • Abstract Number: 856 • 2013 ACR/ARHP Annual Meeting

    Cost-Effectiveness Of Urate Lowering Strategies For The Management Of Gout

    Eric Jutkowitz1, Karen Kuntz2, Laura T Pizzi3 and Hyon Choi4,5, 1Divisions of Health Policy and Management (EJ, KMK), School of Public Health, University of Minnesota, Minneapolis, MN, 2Division of Health Policy and Management, School of Public Health, University of Minnesota, Minneapolis, MN, 3Thomas Jefferson University, Philadelphia, PA, 4Section of Rheumatology and the Clinical Epidemiology, Boston University School of Medicine, Boston, MA, 5Division of Rheumatology, Allergy, and Immunology Massachusetts General Hospital, Harvard Medical School, Boston, MA

    Background/Purpose:  The new 2012 ACR guidelines for the management of gout have provided updated recommendations; however, the employed method do not address the societal costs…
  • Abstract Number: 426 • 2013 ACR/ARHP Annual Meeting

    Characteristics of Protocol-Specified Responders/Non-Responders Treated With Etanercept Plus Methotrexate in Period 1 of the Prize Study

    Paul Emery1, Annette Szumski2, Jack Bukowski3, Eustratios Bananis2 and Lisa Marshall4, 1Institute Rheumatic and Musculoskeletal Medicine University of Leeds, Leeds, United Kingdom, 2Specialty Care, Pfizer Inc., Collegeville, PA, 3Department of Specialty Care, Pfizer Inc, Collegeville, PA, 4Pfizer Inc., Collegeville, PA

    Background/Purpose: Although frequently effective, treatment with synthetic or biologic disease-modifying antirheumatic drugs (DMARDs) does not adequately control disease activity in all patients. Prompt identification of…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2022 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies